Key result
Sera from patients infected with GII.4 and GII.17 noroviruses demonstrated limited cross-immune reactivity by ELISA and little reactivity by HBGA blocking assay.
Why the study?
The antigenic relatedness between the novel GII.17 norovirus variant and the dominant GII.4 noroviruses in China was unclear, limiting understanding of host immune factors in variant emergence.
Does GII.4-specific herd immunity play a role in the emergence of the new GII.17 norovirus variant?
Observational
Does GII.4-specific herd immunity play a role in the emergence of the new GII.17 norovirus variant?
GII.4-specific herd immunity had little role in the emergence of the new GII.17 variant, suggesting GII.17 should be considered for future norovirus vaccines.
A novel GII.17 norovirus variant caused major gastroenteritis epidemics in China in 2014 to 2016. To explore the host immune factors in selection of the emergence of this new variant, we characterized its antigenic relatedness with the GII.4 noroviruses that have dominated in China for decades. Through an enzyme-linked immunosorbent assay (ELISA) and a histo-blood group antigen (HBGA) blocking assay using sera from GII.4 and the GII.17 variant-infected patients, respectively, we observed limited cross-immune reactivity by the ELISA but little reactivity by the HBGA blocking assay between GII.4 norovirus and the new GII.17 variant. Our data suggest that, among other possible factors, GII.4-specific herd immunity had little role in the emergence of the new GII.17 variant. Thus, GII.17 may be an important active antigenic type or immunotype that needs to be considered for future vaccine strategies against human noroviruses.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2017) conducted an observational in Norovirus infection. GII.17 norovirus variant vs. GII.4 norovirus was evaluated on Cross-immune reactivity by ELISA and HBGA blocking assay. Sera from patients infected with GII.4 and GII.17 noroviruses demonstrated limited cross-immune reactivity by ELISA and little reactivity by HBGA blocking assay.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: